Supplementary Figure S5 from The Oncogenic <i>EGFR–SHC1</i> Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer

作者：Jiani Zheng, Shen Zhao, Jianhua Zhan, Weitao Zhuang, Maojian Chen, Wei Jiang, Yihua Huang, Junyi He, Liyang Hu, Lanlan Pang, Feng Hao, Jinhui Xue, Mengting Shi, Anlin Li, Jingxun Wu, Shaodong Hong, Yuanyuan Zhao, Feng Ye, Yan Huang, Hongyun Zhao, Yunpeng Yang, Wenfeng Fang, Li Zhang, Jing Li · 年份：2026 · DOI：10.1158/2159-8290.33143420 · 研究领域：Cancer research、Chemistry、Cell biology、Biology、Molecular biology

<p>Supplementary Figure S5 shows that dual inhibition of afatinib plus SRC-TKIs represents a potential treatment strategy for EGFR-SHC1-driven tumors, including immunoblotting analyses of downstream signaling following combination treatment with afatinib and tirbanibulin, dose-response curves for the combination in Ba/F3-EGFR-SHC1 cells, and validation experiments using SRC knockdown or SHC1-inactivated mutants to confirm that the synergistic effects of dasatinib and afatinib are mediated through SRC-dependent SHC1 signaling.</p>